Morison invests Rs. 4.4 bn in two pharma plants

Previously known as J.L Morison Son & Jones (Ceylon) PLC and now a subsidiary of the Hemas Group have recently invested Rs. 400 million to upgrade their facility in Mutwal Aluthmawatha. In addition, after the acquisition, Hemas Group in 2013, has invested Rs. 4 billion to build a new pharmaceutical manufacturing factory in Homagama which was opened in 2022.

Managing Director J.L. Morison Son & Jones (Ceylon) PLC now re-branded as Morison, Dinesh Attapattu said that the new ultra modern facility now manufactures and has put out five ‘Made in Sri Lanka’ tablets and syrups to the local market.

“We have submitted samples of 25 more ‘Made in Sri Lanka’ pharma products and we hope we will receive approval from the government certification body NMRA to release 10 more products to the local market by this year. He said that their locally made products are of world quality and are of export standard and products that are already in the market have revolutionized the pharma market.

“For example the ground breaking EmpaMor 10 and 25 tables made by us are sold at almost 50% less than the imported product.”

(Research in the market also shows that with the introduction of Morrisons EmpaMor the imported tablet has suddenly come down drastically!) “We expect this to repeat with the introduction of our other products. With the recent Rs. 4 billion investment in the state–of-the-art pharma manufacturing facility at Homagama, Morison embarked on a journey upstream of changing the landscape of the pharma manufacturing industry in Sri Lanka, by nurturing an exclusive homegrown pharma brand built upon a value blend that is uniquely unapparelled.”

He however said that despite the significant presence in the market through the manufacturing of bulk generics for government hospitals and stocking doctor markets, the brand may not be as widely recognized. “Due to this we are now launching a mega campaign among the medical fraternity to increase the use of locally made pharma products.”

He said that they were firstmotivated into moving in investing in the Pharma sector due to the forward buying agreement of the then government in 2015 which was faulted later.

“However we continued and are happy that our products have helped the country to save FOREX from pharma imports.” Today the Homagama facility with 400 members is the largest pharma investment (manufacturing industry) in Sri Lanka while is the only EU GMP compliant general oral solid and liquid dosage (general OSD/OLD) pharma manufacturing facility in Sri Lanka and is the first zero liquid discharge effluent treatment plant in Sri Lanka.

Morisons in 1959 ventured into pharmaceutical manufacturing with its facility at Mutwal.

The post Morison invests Rs. 4.4 bn in two pharma plants appeared first on DailyNews.